期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱![]() | ACTA ONCOLOGICA LetPub Score 6.5
50 ratings
Rate
Reputation 7.5 Influence 5.2 Speed 8.8 | ||||||||||||||||||||||||
期刊簡稱 | ACTA ONCOL | ||||||||||||||||||||||||
ISSN | 0284-186X | ||||||||||||||||||||||||
E-ISSN | 1651-226X | ||||||||||||||||||||||||
h-index | 88 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 7.40%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | http://www.tandfonline.com/toc/ionc20/current#.V3t2DtJ9600 | ||||||||||||||||||||||||
在線稿件提交 | https://mc.manuscriptcentral.com/sonc | ||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||
出版商 | Informa Healthcare | ||||||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||||||
出版國/地區 | NORWAY | ||||||||||||||||||||||||
發行頻率 | 隔月刊行 | ||||||||||||||||||||||||
創刊年 | 1987 | ||||||||||||||||||||||||
每年文章數 | 210每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 34.24% | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0284-186X%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Average 3 Month(s) | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: About 50% | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[ACTA ONCOLOGICA] 的評論 | 撰寫評論 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 13:16:23 評論於 All questions must be answered systematically without omission; try to fulfill any additional experiments suggested in the comments, provide reasonable explanations if some cannot be conducted; make sure to cite the literature recommended by the reviewer and discuss it thoroughly; double-check the modifications made to the initial draft before submitting the revised manuscript ![]() ![]() |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 09:08:02 評論於 After the reviewer completes the scoring of the chapter, they need to write a comprehensive review opinion. This usually includes a brief summary of the article content, evaluation of the article's innovation points, pointing out the shortcomings of the article, and providing suggestions for how the editor should handle the article ![]() ![]() |
作者: 修然小公主 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 23:48:26 評論於 How to respond to reviewer comments? ![]() ![]() |
作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 23:29:16 評論於 What are the opinions and suggestions of the journal editors? What are the opinions and suggestions of the reviewer? What are the differences between the two? ![]() ![]() |
作者: Squires 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2018-09-28 14:50:30 評論於 I feel that this journal has not been very good in the past two years, and the quality has gone down. ![]() ![]() |
作者: Jocelyn Albert 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-09-28 10:57:33 評論於 Review speed: 3.0 Experience sharing: I feel that this journal is not as good as before in the past two years, and the reviewers are not as serious as before ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 08:57:51 評論於 3-point edge, hoping to maintain stability, a slight increase is also good ![]() ![]() |
作者: Gale Onions 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2015-08-23 20:25:04 評論於 Submission success rate: 5.0 Experience sharing: The official magazine of the four Nordic countries, with the majority of authors from these four countries, followed by Europe, a few from the United States, rare from Asia, and none from China in the past two years. The difficulty of submission is very high, with a success rate of about 15% or less. Usually, editors will eliminate a batch of submissions similar to domestic core journals! ![]() ![]() |
作者: 哈罗德耶克斯 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2013-04-12 10:27:07 評論於 Review speed: 3.0 | Submission acceptance rate: 50.0 Experience sharing: In April 2012, I submitted an article to this journal. The first review reply came in one month, saying they were interested and requested revisions (no rejection, I thought the reviewers were kind). So I made the revisions and resubmitted. After two months with no response, I sent a reminder email, and got a quick reply. The reviewers thought the experiments were too simple and requested additional experiments (they were really kind). It took nearly 2 months to complete the additional experiments and resubmit. After one month with no news, I sent another reminder, expressing concern about the lengthy review process and urging for a faster pace. The reply promised faster processing. Less than 2 weeks later, they replied asking for language polishing. After polishing, I resubmitted and received acceptance 3 days later. The whole process took nearly 8 months ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-06-29 20:34:09 評論於 It looks bullish. If it goes up again tomorrow, it is expected to break through 3 points ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-04-16 20:36:58 評論於 EF has just been found in 2009 ![]() ![]() |
作者: 九阴琴心 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-04-16 19:49:49 評論於 EF has just been found in 2009 ![]() ![]() |
作者: Eli Josh 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2010-11-08 10:51:58 評論於 My article was rejected after being reviewed for 3 months. It's very straightforward. A bit frustrated, if they were going to reject it, they should have done it sooner instead of dragging it out for so long ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2009-12-15 20:13:27 評論於 Field: Oncology Country: Sweden Submission Time: May 2006 Review Time: Initial review 8 weeks, major revision once, return after two months, minor revision, then return after two weeks for acceptance. Publication Fee: Free Journal Periodicity: 8 issues per year Personal Comment: This journal is worth considering for colleagues studying tumors. It leans toward the basic side, and its Impact Factor has risen rapidly in recent years, from a few points to a certain difficulty level. Full-text access is available for free online six months after publication ![]() ![]() |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us